Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest diazepam Stories

2012-02-06 14:50:00

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures. Following initial pre-IND discussions with FDA in late 2011, Neurelis filed the IND based upon the encouraging human pharmacokinetic results seen when comparing absolute...

2011-12-06 07:40:00

New Therapy Grants Program Supports Four Innovative Approaches to Treat or Detect Epilepsy Next Grant Award Application Cycle is Now Open WASHINGTON, Dec. 6, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of the two non-profit epilepsy organizations to advance clinical development and commercialization of promising epilepsy...

2011-09-09 08:38:00

BASEL, Switzerland and NUTLEY, N.J., Sept. 9, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome. "There is currently a large unmet medical need for the treatment of cognitive impairments in individuals suffering from Down syndrome," comments Luca Santarelli, Global Head of...

2011-09-06 08:25:00

EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. This action by the European Commission represents the first product approval...

2011-06-22 12:07:00

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study. The propriety formulation was designed and manufactured at Particle Sciences. In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for Diastat® (rectal diazepam gel), the only FDA approved...

2011-06-14 12:37:00

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection. The study was designed and conducted in collaboration with investigators at the University of Minnesota. Comparative analysis of the lead intranasal formulation, NRL-1, revealed promising...

2011-04-20 08:00:00

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection. Through the collaboration with the University of Minnesota and James Cloyd, PharmD; Neurelis has partnered with the leading experts in clinical research of the nasal delivery of benzodiazepines....

2010-06-07 14:03:44

When seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity. In a paper published in the June Academic Emergency Medicine, UC emergency medicine assistant professor Jason McMullan, MD, found that the best means of stopping status epilepticus (SE) may be with the least direct medication. In the meta-analysis, McMullan compiled the results of six studies featuring 774 patients. His analysis...

2009-08-28 18:47:00

BEVERLY HILLS, Calif., Aug. 28 /PRNewswire/ -- The Waismann Method, a pioneering medical opiate detoxification procedure, offers one of the most advanced medical procedures worldwide with the medical expertise and advanced technology to treat dependencies to Benzodiazepines, including Ativan, Xanax, Klonopin and Valium. The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted withdrawal from Benzodiazepines in a hospital setting. This...

315f76eb93e9b8ff5eae23974c0e950d1
2009-06-19 07:20:00

In Germany, a group of researchers believe they may have discovered a more sophisticated anti-anxiety drug capable of controlling panic attacks without the hefty side effects associated with most currently available treatments. Diazepam, the active ingredient in the popular drug Valium, has been used for more than 40 years to treat acute anxiety symptoms.  Though highly effective in helping patients manage panic attacks, Valium is frequently accompanied by a number of unpleasant side...